Dianthus Therapeutics, Inc. /DE/ — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Dianthus reported Q3 2026 net loss of $46.6M ($0.81/share) vs. $36.8M ($0.97/share) YoY. Cash, equivalents, and investments totaled $1.2B as of September 30, 2026, providing projected runway into 2030. R&D expenses increased 40% YoY to $45.6M; G&A rose 72% to $14.1M, driven by higher clinical trial costs and headcount. Pipeline progress includes Phase 3 EMERGE (gMG) top-line expected 2H'28, Phase 3 CAPTIVATE Part A (CIDP) by YE'27 showing 75% interim response rate, Phase 2 MoMeNtum (MMN) top-line expected December 2026, and Phase 1 programs for DNTH212 and DNTH312 on track.
Why this rating
Strong cash position ($1.2B = 200% of market cap) extends runway substantially; however, accelerating burn ($46.6M/quarter) and early-stage pipeline with no approved products create uncertainty. Clinical progress is positive but typical for biotech phase. Execution risk high.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.